See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Baseball
Nintendo
Donald Trump
Natural Disasters
Social Media
European Union
Trade War
Taxes
Golf
Senate
Trade
Published • loading... • Updated

Vaxcyte's Phase 2 pneumococcal vaccine data disappoint Wall Street

Summary by Endpoints News
Vaxcyte’s stock price {$PCVX} dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an experimental pneumococcal vaccine in infants. The company said VAX-24 was non-inferior to Pfizer' ...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
Clinical Trials ArenaClinical Trials Arena

Vaxcyte stock sinks despite Phase II IPD vaccine trial success

Vaxcyte is awaiting data from another vaccine candidate for invasive pneumococcal disease (IPD) before advancing to Phase III.The post Vaxcyte stock sinks despite Phase II IPD vaccine trial success appeared first on Clinical Trials Arena.

Read Full Article
Endpoints NewsEndpoints News

Vaxcyte's Phase 2 pneumococcal vaccine data disappoint Wall Street

Vaxcyte’s stock price {$PCVX} dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an experimental pneumococcal vaccine in infants. The company said VAX-24 was non-inferior to Pfizer' ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endpoints News broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Vaccines

Vaccines

Wall Street

Wall Street

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal